-
Constellation Pharmaceuticals (CNST) Announces Proposed 4M Share Public Offering of Common Stock
-
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Constellation Pharmaceuticals (CNST) Weakness is a Buying Opportunity - RBC
-
Constellation Pharmaceuticals (CNST) PT Raised to $53 at RBC Capital
-
Constellation Pharmaceuticals to Participate in Two Investor Conferences
-
Constellation Pharmaceuticals to Participate in Two Investor Conferences
-
Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
-
Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
-
Constellation Pharmaceuticals (CNST) Prices 6.5M Share Common Offering at $34.50/Sh
-
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Constellation Pharmaceuticals (CNST) Announces Proposed Public Offering of Common Stock
-
Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Constellation Pharmaceuticals (CNST) PT Raised to $42 at RBC Capital
-
Constellation Pharmaceuticals (CNST) a 'High-Conviction Idea' with ASH Confirmed - RBC
-
UPDATE: RBC Capital Starts Constellation Pharmaceuticals (CNST) at Outperform